CTLT * Stock Overview
Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Catalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,020.00 |
| 52 Week High | US$1,020.00 |
| 52 Week Low | US$1,020.00 |
| Beta | 1.16 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 6.77% |
| Change since IPO | -7.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| CTLT * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -0.9% |
| 1Y | n/a | -20.7% | -4.7% |
Return vs Industry: Insufficient data to determine how CTLT * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CTLT * performed against the MX Market.
Price Volatility
| CTLT * volatility | |
|---|---|
| CTLT * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: CTLT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine CTLT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 16,900 | Alessandro Maselli | www.catalent.com |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Catalent, Inc. Fundamentals Summary
| CTLT * fundamental statistics | |
|---|---|
| Market cap | Mex$217.85b |
| Earnings (TTM) | -Mex$20.81b |
| Revenue (TTM) | Mex$87.40b |
2.5x
P/S Ratio-10.5x
P/E RatioIs CTLT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTLT * income statement (TTM) | |
|---|---|
| Revenue | US$4.38b |
| Cost of Revenue | US$3.43b |
| Gross Profit | US$953.00m |
| Other Expenses | US$2.00b |
| Earnings | -US$1.04b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.75 |
| Gross Margin | 21.75% |
| Net Profit Margin | -23.81% |
| Debt/Equity Ratio | 126.9% |
How did CTLT * perform over the long term?
See historical performance and comparison